SlateStone Wealth LLC increased its stake in shares of Teladoc Health, Inc. (NYSE:TDOC) by 2.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,038 shares of the health services provider’s stock after purchasing an additional 259 shares during the period. SlateStone Wealth LLC’s holdings in Teladoc Health were worth $2,006,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of TDOC. tru Independence LLC acquired a new position in shares of Teladoc Health in the fourth quarter valued at approximately $23,996,000. First National Bank of South Miami boosted its holdings in shares of Teladoc Health by 560.0% in the fourth quarter. First National Bank of South Miami now owns 132 shares of the health services provider’s stock valued at $26,000 after buying an additional 112 shares during the period. Berman Capital Advisors LLC boosted its holdings in shares of Teladoc Health by 234.9% in the fourth quarter. Berman Capital Advisors LLC now owns 144 shares of the health services provider’s stock valued at $28,000 after buying an additional 101 shares during the period. Kathmere Capital Management LLC boosted its holdings in shares of Teladoc Health by 228.9% in the fourth quarter. Kathmere Capital Management LLC now owns 148 shares of the health services provider’s stock valued at $30,000 after buying an additional 103 shares during the period. Finally, Corbenic Partners LLC boosted its holdings in shares of Teladoc Health by 136.4% in the fourth quarter. Corbenic Partners LLC now owns 156 shares of the health services provider’s stock valued at $31,000 after buying an additional 90 shares during the period. 51.77% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently weighed in on TDOC shares. Jefferies Financial Group reduced their price target on shares of Teladoc Health from $264.00 to $248.00 and set a “hold” rating for the company in a report on Wednesday, March 3rd. Oppenheimer increased their target price on shares of Teladoc Health from $250.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, March 3rd. BTIG Research increased their price objective on shares of Teladoc Health from $260.00 to $330.00 and gave the company a “buy” rating in a research report on Tuesday, January 26th. SVB Leerink increased their price objective on shares of Teladoc Health from $256.00 to $266.00 and gave the company an “outperform” rating in a research report on Wednesday, March 3rd. Finally, Piper Sandler dropped their price objective on shares of Teladoc Health from $305.00 to $291.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 3rd. Fourteen equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $241.18.

TDOC stock opened at $178.85 on Wednesday. The company has a current ratio of 6.52, a quick ratio of 6.47 and a debt-to-equity ratio of 0.43. The company’s 50 day moving average is $188.34 and its 200 day moving average is $214.76. The stock has a market cap of $27.59 billion, a price-to-earnings ratio of -126.51 and a beta of 0.30. Teladoc Health, Inc. has a 1-year low of $147.71 and a 1-year high of $308.00.

Teladoc Health (NYSE:TDOC) last issued its earnings results on Wednesday, February 24th. The health services provider reported ($3.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($2.82). The firm had revenue of $383.32 million during the quarter, compared to analysts’ expectations of $380.39 million. Teladoc Health had a negative return on equity of 6.15% and a negative net margin of 12.71%. As a group, sell-side analysts forecast that Teladoc Health, Inc. will post -1.12 EPS for the current fiscal year.

In related news, insider Yulun Wang sold 8,000 shares of Teladoc Health stock in a transaction dated Friday, January 22nd. The stock was sold at an average price of $260.00, for a total value of $2,080,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Arnnon Geshuri sold 350 shares of Teladoc Health stock in a transaction dated Tuesday, March 16th. The stock was sold at an average price of $205.00, for a total value of $71,750.00. Following the completion of the sale, the insider now owns 97,267 shares of the company’s stock, valued at $19,939,735. The disclosure for this sale can be found here. Insiders have sold 495,443 shares of company stock valued at $95,244,192 over the last 90 days. Corporate insiders own 3.42% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.

Read More: What are earnings reports?

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.